Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children
Status:
Recruiting
Trial end date:
2024-04-13
Target enrollment:
Participant gender:
Summary
This is an interventional, single center, single arm clinical trial to assess the
pharmacokinetics, safety, efficacy, and acceptability of daclatasvir plus sofosbuvir in
treatment-naïve children weighing between 14 and 35 kg with chronic HCV GT 1-6 infection.